Table 2.

Inhibitory effect of EFV uptake.

Compounds		Relative Uptake (% of Control)
		TR-iBRB2 Cells [27]				Lysosome-Enriched Fraction of TR-iBRB2 Cells				Lysosome-Enriched Fraction of RPE-J Cells
Control		100	±	3		100	±	3		100	±	7
Desipramine		47.9	±	2.2 **		61.8	±	1.9 *		65.5	±	5.8 *
Imipramine		55.2	±	2.7 **		68.5	±	2.8		82.5	±	11.0
Propranolol		55.4	±	2.5 **		108	±	13		114	±	7
Verapamil		64.7	±	1.2 **		71.5	±	3.0		51.0	±	3.8 **
Pyrilamine		72.6	±	2.3 **		143	±	1		122	±	12
Clonidine		90.3	±	6.6		132	±	7		98.6	±	4.1
Nicotine		79.5	±	6.0 **		147	±	23		110	±	10

By using TR-iBRB2 cells and lysosome-enriched fractions, the uptake of EFV (1 μM) by was examined in the presence of compounds (100 μM) at 37 °C for 3 min. Each value represents the means ± S.E.M. (n = 4). * p < 0.05, ** p < 0.01, significantly different from the control (absence of inhibitor). EFV, EverFluor FL Verapamil. Data for EFV uptake by TR-iBRB2 cells was presented by reference to previous report [27].